Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study

Overview of attention for article published in Clinical Rheumatology, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets

twitter: 8 X users

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 2 news stories from 2 outlets.

In RA Remission? Halve the Xeljanz Dose

Medical Health News, 13 Aug 2019

Dose reduction was feasible for patients with rheumatoid arthritis who achieved remission or low disease activity with…

In RA Remission? Halve the Xeljanz Dose

MedPage Today, 12 Aug 2019

Dose reduction was feasible for patients with rheumatoid arthritis who achieved remission or low disease activity with…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.